Patents by Inventor John Knopf

John Knopf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Activin-ActRIIa antagonists and uses for promoting bone growth
    Patent number: 7951771
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Grant
    Filed: September 24, 2008
    Date of Patent: May 31, 2011
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • Nucleic acids encoding IL-13 binding agents
    Patent number: 7943342
    Abstract: Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.
    Type: Grant
    Filed: January 22, 2009
    Date of Patent: May 17, 2011
    Assignee: Wyeth LLC
    Inventors: Lioudmila Tchistiakova, Marion T. Kasaian, Debra D. Donaldson, Xiang-Yang Tan, Davinder Gill, Macy X. Jin, Bruce Jacobson, Samuel J. Goldman, John Knopf, Angela M. Widom
  • VARIANTS DERIVED FROM ACTRIIB AND USES THEREFOR
    Publication number: 20110092670
    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.
    Type: Application
    Filed: September 29, 2010
    Publication date: April 21, 2011
    Applicant: ACCELERON PHARMA INC.
    Inventors: JOHN KNOPF, JASBIR SEEHRA, RAVINDRA KUMAR
  • ACTRIIB ANTAGONISTS AND DOSING AND USES THEREOF
    Publication number: 20110070233
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma. Methods for dosing a patient with an ActRIIb antagonist are also provided.
    Type: Application
    Filed: September 9, 2010
    Publication date: March 24, 2011
    Applicant: ACCELERON PHARMA INC.
    Inventors: JASBIR SEEHRA, JOHN KNOPF, Kenneth M. ATTIE
  • USES OF CERBERUS AND DERIVATIVES THEREOF
    Publication number: 20110046057
    Abstract: The disclosure relates to Cerberus/Coco polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11.
    Type: Application
    Filed: November 5, 2010
    Publication date: February 24, 2011
    Applicant: Acceleron Pharma Inc.
    Inventors: Asya Grinberg, John Knopf, Ravindra Kumar, Jasbir Seehra
  • ALK7 AND MYOSTATIN INHIBITORS AND USES THEREOF
    Publication number: 20100322925
    Abstract: The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.
    Type: Application
    Filed: August 20, 2010
    Publication date: December 23, 2010
    Applicant: ACCELERON PHARMA INC.
    Inventors: JOHN KNOPF, JASBIR SEEHRA
  • METHODS FOR INCREASING THERMOGENIC ADIPOCYTES
    Publication number: 20100310577
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
    Type: Application
    Filed: June 8, 2010
    Publication date: December 9, 2010
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • Variants derived from ActRIIB and uses therefor
    Patent number: 7842663
    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.
    Type: Grant
    Filed: February 4, 2008
    Date of Patent: November 30, 2010
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • Uses of cerberus, coco and derivatives thereof
    Patent number: 7833971
    Abstract: The disclosure relates to Cerberus/Coco polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11.
    Type: Grant
    Filed: December 10, 2007
    Date of Patent: November 16, 2010
    Assignee: Acceleron Pharma Inc.
    Inventors: Asya Grinberg, John Knopf, Ravindra Kumar, Jasbir Seehra
  • ACRTIIB-FC POLYNUCLEOTIDES, POLYPEPTIDES, AND COMPOSITIONS
    Publication number: 20100267133
    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuron. The present invention also provides methods of screening compounds that modulate activity of an ActRII protein and/or an ActRII ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRII protein and/or an ActRII ligand.
    Type: Application
    Filed: March 31, 2010
    Publication date: October 21, 2010
    Applicant: ACCELERON PHARMA INC.
    Inventors: JOHN KNOPF, JASBIR SEEHRA
  • Methods of promoting growth of muscle tissue using ALK7
    Patent number: 7807631
    Abstract: The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: October 5, 2010
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • Cerberus/coco derivatives and uses thereof
    Publication number: 20100183695
    Abstract: The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives.
    Type: Application
    Filed: May 27, 2005
    Publication date: July 22, 2010
    Inventors: John Knopf, Jasbir Seehra
  • Lefty, lefty derivatives and uses thereof
    Publication number: 20100160225
    Abstract: The disclosure relates to Lefty derivatives and the uses of Lefty polypeptides as antagonists of the function of certain ligands such as Nodal, GDF-8 (Myostatin), and GDF-11. These derivatives may be fused to other functional heterologous proteins such as IgG, especially the Fc portion of IgG. According to the disclosure, Lefty polypeptides are useful in the treatment of a variety of disorders, including, for example, neuronal diseases, muscle and bone conditions, and metabolic disorders.
    Type: Application
    Filed: September 18, 2009
    Publication date: June 24, 2010
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • BMP10 propeptides and related methods
    Patent number: 7741284
    Abstract: In certain aspects, the present invention provides BMP10 propeptides for use in treating a variety of disorders including heart disorders and other disorders associated with unwanted activity of the mature BMP10 polypeptide. The present invention also provides methods of screening compounds that modulate activity of BMP10.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: June 22, 2010
    Assignee: Acceleron Pharma Inc.
    Inventors: Jasbir Seehra, John Knopf
  • ActRII receptor polypeptides, methods and compositions
    Patent number: 7709605
    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuron. The present invention also provides methods of screening compounds that modulate activity of an ActRII protein and/or an ActRII ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRII protein and/or an ActRII ligand.
    Type: Grant
    Filed: July 25, 2005
    Date of Patent: May 4, 2010
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION
    Publication number: 20090311272
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
    Type: Application
    Filed: May 1, 2009
    Publication date: December 17, 2009
    Inventors: Asya Grinberg, John Knopf, Ravindra Kumar, Robert S. Pearsall, Jasbir Seehra, Kristian Pietras
  • Anti-activin antibodies and uses for promoting bone growth
    Publication number: 20090311252
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Application
    Filed: May 6, 2009
    Publication date: December 17, 2009
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • ANTAGONISTS OF BMP9, BMP10, ALK1 AND OTHER ALK1 LIGANDS, AND USES THEREOF
    Publication number: 20090304691
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of BMP9 and/or BMP10, ligands for ALK1, may also be used to inhibit angiogenesis in vivo.
    Type: Application
    Filed: May 15, 2009
    Publication date: December 10, 2009
    Applicant: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, John Knopf, Robert S. Pearsall, Asya Grinberg, Ravindra Kumar
  • BMP-3 propeptides and related methods
    Patent number: 7625867
    Abstract: The present invention provides compositions and methods for promoting bone growth. The present invention also provides methods of screening compounds that modulate BMP-3A or BMP-3B activity. The compositions and methods provided herein are useful in modulating bone growth.
    Type: Grant
    Filed: March 28, 2005
    Date of Patent: December 1, 2009
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jabir Seehra
  • IL-13 BINDING AGENTS
    Publication number: 20090274705
    Abstract: Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.
    Type: Application
    Filed: January 22, 2009
    Publication date: November 5, 2009
    Applicant: WYETH
    Inventors: Lioudmila Tchistiakova, Marion T. Kasaian, Debra D. Donaldson, Xiang-Yang Tan, Davinder Gill, Macy X. Jin, Bruce Jacobson, Samuel J. Goldman, John Knopf, Angela M. Widom